415 related articles for article (PubMed ID: 32938499)
1. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system.
Huang J; Jia Y; Sun S; Meng L
BMC Pharmacol Toxicol; 2020 Sep; 21(1):68. PubMed ID: 32938499
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
[TBL] [Abstract][Full Text] [Related]
3. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
Jedlowski PM; Jedlowski MF; Fazel MT
Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Baksh SN; McAdams-DeMarco M; Segal JB; Alexander GC
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):660-667. PubMed ID: 29655237
[TBL] [Abstract][Full Text] [Related]
5. Pharmacovigilance study of the association between dipeptidyl peptidase-4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS).
Ohyama K; Shindo J; Takahashi T; Takeuchi H; Hori Y
Sci Rep; 2022 Jul; 12(1):13122. PubMed ID: 35907939
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events.
Rahman MM; Scalese MJ; Hansen RA
Ann Pharmacother; 2017 Jul; 51(7):563-569. PubMed ID: 28166651
[TBL] [Abstract][Full Text] [Related]
7. Signal Detection for Cardiovascular Adverse Events of DPP-4 Inhibitors Using the Korea Adverse Event Reporting System Database, 2008-2016.
Yi H; Lee JH; Shin JY
Yonsei Med J; 2019 Feb; 60(2):200-207. PubMed ID: 30666842
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl Peptidase-4 Inhibitor-Associated Pancreatic Carcinoma: A Review of the FAERS Database.
Nagel AK; Ahmed-Sarwar N; Werner PM; Cipriano GC; Van Manen RP; Brown JE
Ann Pharmacother; 2016 Jan; 50(1):27-31. PubMed ID: 26497885
[TBL] [Abstract][Full Text] [Related]
9. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS.
Ji HH; Tang XW; Dong Z; Song L; Jia YT
Clin Drug Investig; 2019 Mar; 39(3):319-330. PubMed ID: 30674039
[TBL] [Abstract][Full Text] [Related]
10. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
11. Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System.
Huang L; Liu Y; Li H; Huang W; Geng R; Tang Z; Jiang Y
Int J Med Sci; 2021; 18(9):1946-1952. PubMed ID: 33850463
[No Abstract] [Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system.
Lu W; Sun S; Wei J; Thai S; Li D; Tang H; Wang T; Sun L
Int J Clin Pharm; 2020 Oct; 42(5):1364-1368. PubMed ID: 32951183
[TBL] [Abstract][Full Text] [Related]
13. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
Zhang S; Wang Y; Qi Z; Tong S; Zhu D
Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
[TBL] [Abstract][Full Text] [Related]
14. Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022).
Ren X; Wang H; Deng L; Wang W; Wang Y
Int Immunopharmacol; 2024 Jul; 136():112301. PubMed ID: 38838553
[TBL] [Abstract][Full Text] [Related]
15. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
Shimada K; Hasegawa S; Nakao S; Mukai R; Matsumoto K; Tanaka M; Uranishi H; Masuta M; Nishida S; Shimizu S; Hayashi Y; Suzuki A; Nakamura M
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1097-1105. PubMed ID: 31502115
[TBL] [Abstract][Full Text] [Related]
16. Inverse association between DPP-4 inhibitor use and fracture in older adults: A disproportionality analysis of the FAERS and JADER.
Ohyama K; Okamoto T; Hori Y
Int J Clin Pharmacol Ther; 2023 Jan; 61(1):16-23. PubMed ID: 36366967
[TBL] [Abstract][Full Text] [Related]
17. Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system.
Antonazzo IC; Poluzzi E; Forcesi E; Salvo F; Pariente A; Marchesini G; De Ponti F; Raschi E
Acta Diabetol; 2020 Jan; 57(1):71-80. PubMed ID: 31203438
[TBL] [Abstract][Full Text] [Related]
18. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.
Willemen MJ; Mantel-Teeuwisse AK; Straus SM; Meyboom RH; Egberts TC; Leufkens HG
Diabetes Care; 2011 Feb; 34(2):369-74. PubMed ID: 21270195
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Adverse Events Occurred During Administration of Dipeptidyl Peptidase-4 Inhibitor in Patients with Diabetes Using FDA Adverse Event Reporting System.
Ogura T; Shiraishi C
Clin Drug Investig; 2023 Feb; 43(2):129-140. PubMed ID: 36637688
[TBL] [Abstract][Full Text] [Related]
20. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.
Yin G; Song G; Xue S; Liu F
Sci Rep; 2024 May; 14(1):11367. PubMed ID: 38762547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]